Drug resistance interpretation: PR HIVDB 9.5.1 (2023-11-05)

PI Major Mutations: None
PI Accessory Mutations: Q58E

PR Other Mutations: L10X • V11S • T12\* • I13\* • K14I • I15W • G17K • Q18T • L19P • E21F • A22I • L23G • L24P • D25I • T26Q • G27R • A28T • D29Y • D30\* • M36I • N37Y • D60E • L63P • I64V

### Protease Inhibitors

 atazanavir/r (ATV/r)
 Susceptible

 darunavir/r (DRV/r)
 Susceptible

 fosamprenavir/r (FPV/r)
 Susceptible

 indinavir/r (IDV/r)
 Susceptible

 lopinavir/r (LPV/r)
 Susceptible

nelfinavir (NFV) Potential Low-Level Resistance

saquinavir/r (SQV/r) Susceptible

tipranavir/r (TPV/r) Low-Level Resistance

### PR comments

### Accessory

Q58E is a minimally polymorphic accessory mutation selected by each of the PIs except DRV. In combination with other PI-resistance mutations, it may contribute to low-level ATV resistance.

### Other

L24I is a non-polymorphic mutation selected by IDV and LPV. It contributes reduced susceptibility to ATV and LPV. L24F/M are uncommon non-polymorphic PI-selected mutations. L24F has a susceptibility profile similar to L24I. L24P is a highly unusual mutation at this position.

# Drug resistance mutation scores of PI:

Mutation scoring: PR

tenofovir (TDF)

Download CSV

Rule	ATV/r \$	DRV/r \$	FPV/r \$	IDV/r ‡	LPV/r \$	NFV \$	sqv/r =	TPV/r ‡
Q58E	0	0	0	0	0	10	0	15

Intermediate Resistance

## Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations: M41L • K65R • S68N • L74I • M184V

NNRTI Mutations: K103N • P225H

RT Other Mutations: K20R • V60I • D121Y • K122E • I135T • I142T • S162C • Q174E • Q207K • K219I • K220\* • K223R • L228Q • W239X • V245A • D250E • D256E • K263\* • W266\* • G273E • I274S • K275E • V276L • K281N • L282A • L283I • G285E • T286P • K287I • A288H • L289\* • T290Q • I293V • P294V

## Nucleoside Reverse Transcriptase Inhibitors

# Non-nucleoside Reverse Transcriptase Inhibitors

abacavir (ABC) High-Level Resistance doravirine (DOR) Intermediate Resistance zidovudine (AZT) Susceptible efavirenz (EFV) High-Level Resistance stavudine (D4T) High-Level Resistance etravirine (ETR) Susceptible High-Level Resistance High-Level Resistance didanosine (DDI) nevirapine (NVP) emtricitabine (FTC) High-Level Resistance rilpivirine (RPV) Susceptible lamivudine (3TC) High-Level Resistance

Drug	resistance	mutatio	n scores o	f NRTI:

Rule	AE	BC ≑	AZT ≑	D4T ≑	DDI 🕏	FTC ‡	зтс ≑	TDF
M41L		5	15	15	10	0	0	5
K65R		45	-10	60	60	30	30	50
<u>L741</u>		15	0	0	60	0	0	5
M184V		15	-10	-10	10	60	60	-10
K65R + S6	8N	0	0	0	0	0	0	5
Total		80	-5	65	140	90	90	55

Drug resistance mutation scores of NNPTI-



Drug resistance muti		Download CSV			
Rule	DOR ÷	EFV \$	ETR ‡	NVP ≎	RPV =
K103N + P225H	10	0	0	0	0
P225H	20	45	0	45	0
K103N	0	60	0	60	0
Total	30	105	0	105	0